D1.342 - Therapeutic Potential of LCAA-PSF in Atopic Dermatitis: Insights from an MC903-Induced Mouse Model

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus and impaired skin barrier function, significantly reducing patients' quality of life. Current therapies, such as topical corticosteroids and systemic agents, are limited by heterogeneous responses, disease complexity, and poor adherence. There is growing interest in natural extracts as alternative therapeutic strategies. This study aimed to evaluate the efficacy and underlying mechanisms of a novel emulsion formulation, LCAA-PSF, in alleviating AD-associated inflammation and pathology.

An experimental study using an MC903-induced AD murine model was conducted to assess the therapeutic potential of LCAA-PSF. LCAA-PSF, comprising Lecigel, Cetiol CC, Activonol-6, Activonol-M, 1,3-Propanediol, Soline, and Fucocert, was applied topically to AD-induced mice. Animals were divided into control, AD, LCAA+AD, and AD+LCAA-PSF groups. Clinical and histopathological assessments included erythema, skin morphology, hydration, scratching behavior, desquamation, wound size, and tissue thickness. RNA sequencing, ELISA, and immunohistochemistry were used to investigate molecular mechanisms.  

LCAA-PSF significantly improved AD-related symptoms, including reduced erythema, scratching frequency, epidermal thickening, and enhanced skin hydration. Histopathology revealed decreased mast cell infiltration and epidermal thickening in both ear and dorsal skin. RNA sequencing identified inhibition of Th2-driven JAK-STAT and T-cell receptor signaling pathways. ELISA showed lower serum levels of IL-4, IL-5, and IL-13, corroborated by immunohistochemical evidence of reduced JAK and STAT protein expression.

LCAA-PSF demonstrates significant anti-inflammatory and immunomodulatory effects by targeting the JAK-STAT signaling pathway in an AD murine model. These findings position LCAA-PSF as a promising adjunctive therapy for AD, offering a potential new approach to disease management.